UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies
| Status: | Withdrawn |
|---|---|
| Conditions: | Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | July 2006 |
| End Date: | March 2011 |
The researchers want to find out if subjects treated on this study will achieve long term
bone marrow recovery (engraftment) and if their tumors will respond to this treatment.
bone marrow recovery (engraftment) and if their tumors will respond to this treatment.
Inclusion Criteria:
- Patients with advanced hematological malignancies who have failed at least two lines
of therapy.
- Karnofsky performance score > 60, unless due to disease and then > 50.
- Age > 18 years.
- An expected survival of > 3 months.
- Subjects must have signed an IRB-approved consent and been informed about the
investigational nature of the study.
- Cord blood must have negative serology for HIV.
- Release of cord blood.
- The nucleated cell count of the CBU shall equal or exceed 1 x 107 per kg of recipient
body weight.
Exclusion Criteria:
- Liver function: total bilirubin > 2x ULN or AST/ALT > 3x ULN.
- Creatinine > 3.0 mg/dL.
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
